

## Kyowa Hakko Kirin Revises Forecasts

**Tokyo, July 20, 2011** – In consideration of recent performance trends, Kyowa Hakko Kirin Co, Ltd. (Kyowa Hakko Kirin, TSE: 4151) has revised its interim and full-year results forecasts that were previously announced on January 28, 2011, as follows:

### Revised forecasts

Revised consolidated results forecasts for the interim period of fiscal 2011 (January 1, 2011 to June 30, 2011)

	<i>Millions of yen</i>				
	Net sales	Operating income	Recurring income	Net income	Net income per share (¥)
Previous forecasts (A)	175,000	20,000	20,500	14,500	25.45
Revised forecasts (B)	186,300	29,900	30,200	17,700	31.10
Change in forecasts (B-A)	11,300	9,900	9,700	3,200	
Percentage change	6.5	49.5	47.3	22.1	
Reference: Results for the interim period of the fiscal year ended December 31, 2010	203,466	21,692	22,334	9,901	17.38

Revised consolidated results forecasts for fiscal 2011 (January 1, 2011 to December 31, 2011)

	<i>Millions of yen</i>				
	Net sales	Operating income	Recurring income	Net income	Net income per share (¥)
Previous forecasts (A)	325,000	37,000	38,000	25,500	44.75
Revised forecasts (B)	342,000	43,500	44,500	25,500	44.75
Change in forecasts (B-A)	17,000	6,500	6,500	--	
Percentage change	5.2	17.6	17.1	--	
Reference: Results for the fiscal year ended December 31, 2010	413,738	45,410	46,500	22,197	38.96

### Reasons for the forecast revisions:

In consolidated results for the interim period, in the Pharmaceuticals business, sales of core ethical pharmaceutical product Nesp, a treatment for renal anemia were strong, while sales of Allelock, an antiallergic agent, and Patanol antiallergic eye drops, were at higher levels than originally forecast and higher than in the same period of the previous fiscal year due to the effects of increased amounts of airborne pollen in Japan. Sales of Regpara, a treatment for secondary hyperparathyroidism during dialysis therapy, Asacol, an ulcerative colitis treatment, and Fentos, a transdermal analgesic for persistent cancer pain launched last year, were also robust. Additionally, a certain amount of the SG&A budget, primarily in regard to R&D, is expected to be unused and as a result the interim and full year consolidated results forecasts have been revised.

*This document is an English translation of the Japanese-language original. All financial information has been prepared in accordance with generally accepted accounting principles in Japan. It contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. Actual financial results may differ materially depending on a number of factors, including fluctuations in exchange rates, changing economic conditions, legislative and regulatory developments, delays in new product launches, and pricing and product initiatives of competitors.*

The above forecasts are based on information available and assumptions made at the time of release of this document about a number of uncertain factors that can affect results in the future. It is possible that actual results are materially different for a wide variety of reasons.

\* \* \* \* \*

**Contact:** Mr. Hidenori Ishii, Corporate Communications Department

Tel: 81 3 3282 0247

hidenori.ishii@kyowa-kirin.co.jp

For further information please access: <http://www.kyowa-kirin.co.jp/english/index.html>

*This document is an English translation of the Japanese-language original. All financial information has been prepared in accordance with generally accepted accounting principles in Japan. It contains forward-looking statements based on a number of assumptions and beliefs made by management in light of information currently available. Actual financial results may differ materially depending on a number of factors, including fluctuations in exchange rates, changing economic conditions, legislative and regulatory developments, delays in new product launches, and pricing and product initiatives of competitors.*